Abstract
© 2016, © 2016 World Stroke Organization. Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.
Original language | English |
---|---|
Pages (from-to) | 9-12 |
Journal | International Journal of Stroke |
Volume | 12 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2017 |
Keywords
- dabigatran
- idarucizumab
- Ischemic stroke
- rt-PA
- thrombectomy
- thrombolysis